All In Biotech

Drug Trial Radar · NCT06990529

Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Apr 29, 2025

Primary completion

Aug 12, 2029

Study completion Aug 12, 2029

Sponsor

Lead sponsor
Pharming Technologies B.V.Industry
Sponsor type
Industry
Collaborators
Aixial Group
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label extension (OLE) study to extend treatment to patients with primary immunodeficiency (PID) disorders linked to phosphoinositide 3-kinase delta signaling who participated in a prior study of leniolisib, LE 7201. The primary objective is to assess long-term safety and tolerability of leniolisib. Secondary and exploratory objectives include various efficacy and immunophenotyping measures for leniolisib.

Conditions

  • PIDs Linked to PI3K

Interventions

  • LeniolisibDrug

    All subjects will receive leniolisib film-coated tablets (FCTs) at the same dose they were receiving when they completed the preceding study (10, 30, or 70 mg twice daily \[BID\]).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the long-term safety and tolerability of leniolisibTime frame: From Baseline to approximately 3 years of Treatment

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • National Institute of Health

    Bethesda, Maryland

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts

  • Mount Sinai Hospital

    New York, New York

  • IIS La Fe

    Valencia, Spain

  • St James Hospital

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.